1. Korfel, A. et al. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clinical Cancer Research 4, 2701–2708 (1998).
2. Christodoulou, C. V. et al. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. Journal of Clinical Oncology 16, 2761–2769 (1998).
3. Mross, K. et al. Phase I clinical trial of a day-1, -3, -5 every 3 weeks schedule with titanocene dichloride (mkt 5) in patients with advanced cancer: a study of the phase I study group of the association for medical oncology (AIO) of the german cancer society. Onkologie 23, 576–579 (2000).
4. Lümmen, G., Sperling, H., Luboldt, H., Otto, T. & Rübben, H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemotherapy and Pharmacology 42, 415–417 (1998).
5. Kröger, N., Kleeberg, U., Mross, K., Edler, L. & Hossfeld, D. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Oncology Research and Treatment 23, 60–62 (2000).